Cystatin C is not a good candidate biomarker for HNF1A-MODY.

2.50
Hdl Handle:
http://hdl.handle.net/11287/619171
Title:
Cystatin C is not a good candidate biomarker for HNF1A-MODY.
Authors:
Nowak, N.; Szopa, M.; Thanabalasingham, G.; McDonald, Timothy J. ( 0000-0003-3559-6660 ) ; Colclough, K.; Skupien, J.; James, T. J.; Kiec-Wilk, B.; Kozek, E.; Mlynarski, W.; Hattersley, Andrew T.; Owen, K. R.; Malecki, M. T.
Abstract:
Cystatin C is a marker of glomerular filtration rate (GFR). Its level is influenced, among the others, by CRP whose concentration is decreased in HNF1A-MODY. We hypothesized that cystatin C level might be altered in HNF1A-MODY. We aimed to evaluate cystatin C in HNF1A-MODY both as a diagnostic marker and as a method of assessing GFR. We initially examined 51 HNF1A-MODY patients, 56 subjects with type 1 diabetes (T1DM), 39 with type 2 diabetes (T2DM) and 43 non-diabetic individuals (ND) from Poland. Subjects from two UK centres were used as replication panels: including 215 HNF1A-MODY, 203 T2DM, 39 HNF4A-MODY, 170 GCK-MODY, 17 HNF1B-MODY and 58 T1DM patients. The data were analysed with additive models, adjusting for gender, age, BMI and estimated GFR (creatinine). In the Polish subjects, adjusted cystatin C level in HNF1A-MODY was lower compared with T1DM, T2DM and ND (p < 0.05). Additionally, cystatin C-based GFR was higher than that calculated from creatinine level (p < 0.0001) in HNF1A-MODY, while the two GFR estimates were similar or cystatin C-based lower in the other groups. In the UK subjects, there were no differences in cystatin C between HNF1A-MODY and the other diabetic subgroups, except HNF1B-MODY. In UK HNF1A-MODY, cystatin C-based GFR estimate was higher than the creatinine-based one (p < 0.0001). Concluding, we could not confirm our hypothesis (supported by the Polish results) that cystatin C level is altered by HNF1A mutations; thus, it cannot be used as a biomarker for HNF1A-MODY. In HNF1A-MODY, the cystatin C-based GFR estimate is higher than the creatinine-based one.
Citation:
Cystatin C is not a good candidate biomarker for HNF1A-MODY. 2013, 50 (5):815-20 Acta Diabetol
Publisher:
Springer
Journal:
Acta diabetologica
Issue Date:
Oct-2013
URI:
http://hdl.handle.net/11287/619171
DOI:
10.1007/s00592-012-0378-1
PubMed ID:
22350134
Additional Links:
http://link.springer.com/article/10.1007%2Fs00592-012-0378-1
Note:
This article is freely available via Open Access. Click on the ‘Additional Link’ above to access the full-text from the publisher’s site.
Type:
Research Support, Non-U.S. Gov't
Language:
en
ISSN:
1432-5233
Appears in Collections:
pre-2014 RD&E publications; Diabetes/Endocrine Services

Full metadata record

DC FieldValue Language
dc.contributor.authorNowak, N.en
dc.contributor.authorSzopa, M.en
dc.contributor.authorThanabalasingham, G.en
dc.contributor.authorMcDonald, Timothy J.en
dc.contributor.authorColclough, K.en
dc.contributor.authorSkupien, J.en
dc.contributor.authorJames, T. J.en
dc.contributor.authorKiec-Wilk, B.en
dc.contributor.authorKozek, E.en
dc.contributor.authorMlynarski, W.en
dc.contributor.authorHattersley, Andrew T.en
dc.contributor.authorOwen, K. R.en
dc.contributor.authorMalecki, M. T.en
dc.date.accessioned2016-09-01T09:49:37Z-
dc.date.available2016-09-01T09:49:37Z-
dc.date.issued2013-10-
dc.identifier.citationCystatin C is not a good candidate biomarker for HNF1A-MODY. 2013, 50 (5):815-20 Acta Diabetolen
dc.identifier.issn1432-5233-
dc.identifier.pmid22350134-
dc.identifier.doi10.1007/s00592-012-0378-1-
dc.identifier.urihttp://hdl.handle.net/11287/619171-
dc.description.abstractCystatin C is a marker of glomerular filtration rate (GFR). Its level is influenced, among the others, by CRP whose concentration is decreased in HNF1A-MODY. We hypothesized that cystatin C level might be altered in HNF1A-MODY. We aimed to evaluate cystatin C in HNF1A-MODY both as a diagnostic marker and as a method of assessing GFR. We initially examined 51 HNF1A-MODY patients, 56 subjects with type 1 diabetes (T1DM), 39 with type 2 diabetes (T2DM) and 43 non-diabetic individuals (ND) from Poland. Subjects from two UK centres were used as replication panels: including 215 HNF1A-MODY, 203 T2DM, 39 HNF4A-MODY, 170 GCK-MODY, 17 HNF1B-MODY and 58 T1DM patients. The data were analysed with additive models, adjusting for gender, age, BMI and estimated GFR (creatinine). In the Polish subjects, adjusted cystatin C level in HNF1A-MODY was lower compared with T1DM, T2DM and ND (p < 0.05). Additionally, cystatin C-based GFR was higher than that calculated from creatinine level (p < 0.0001) in HNF1A-MODY, while the two GFR estimates were similar or cystatin C-based lower in the other groups. In the UK subjects, there were no differences in cystatin C between HNF1A-MODY and the other diabetic subgroups, except HNF1B-MODY. In UK HNF1A-MODY, cystatin C-based GFR estimate was higher than the creatinine-based one (p < 0.0001). Concluding, we could not confirm our hypothesis (supported by the Polish results) that cystatin C level is altered by HNF1A mutations; thus, it cannot be used as a biomarker for HNF1A-MODY. In HNF1A-MODY, the cystatin C-based GFR estimate is higher than the creatinine-based one.en
dc.language.isoenen
dc.publisherSpringeren
dc.relation.urlhttp://link.springer.com/article/10.1007%2Fs00592-012-0378-1en
dc.rightsArchived with thanks to Acta diabetologicaen
dc.subjectWessex Classification Subject Headings::Endocrinology::Diabetesen
dc.titleCystatin C is not a good candidate biomarker for HNF1A-MODY.en
dc.typeResearch Support, Non-U.S. Gov'ten
dc.identifier.journalActa diabetologicaen
dc.description.noteThis article is freely available via Open Access. Click on the ‘Additional Link’ above to access the full-text from the publisher’s site.en
dc.description.fundingDHCS/07/07/008/Department of Health/United Kingdomen
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.